8 current records
Recalls, warnings, approvals and regulatory shifts that materially affect consumers.
The FDA and CDC closed the investigation after 131 reported cases across 38 states. The products have long shelf lives.
The 2026 guidance says as much as 45% of dementia risk may be attributable to modifiable factors across the life course.
The July update covers products marketed for sexual enhancement, weight loss, muscle building and other uses.
The June guidance explains authorised claims, interactions and why supplement labels cannot promise to treat symptoms.
The FDA database lists the DEP100 as substantially equivalent in a May 2026 decision.
The EMA programme gives selected high-risk devices a route to scientific advice before wider expansion in 2027.
Testing found DMAA, DMHA and phenibut across two products; only one was voluntarily recalled.
The February decision removed specific cardiovascular, breast-cancer and probable-dementia statements from the most prominent warning box.